Seven-year data shows accuray tomotherapy® system provides excellent long-term control of low-risk breast cancer

Sunnyvale, calif., jan. 19, 2021 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that data from a prospective, phase ii trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated...

ARAY Ratings Summary

ARAY Quant Ranking